Product Description
Mechanisms of Action:
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/11/2024 |
PubMed |
CGI1746 targets sigma(1)R to modulate ferroptosis through mitochondria-associated membranes. |
|
12/01/2023 |
PubMed |
Corrigendum: Two small-molecule inhibitors of Toxoplasma gondii proliferation in vitro. |
|
04/03/2023 |
PubMed |
Two small-molecule inhibitors of Toxoplasma gondii proliferation in vitro. |